SYnAbs generates innovative monoclonal antibodies against:
SYnAbs unique technologies (SYnDNA vector, SYnCell syngeneic cell, in-house adjuvant) coupled with its strong expertise in breaking immune tolerance in proprietary rat-LOU species, ensure the generation of high specificity and higher affinity antibodies, benefiting from natural in-vivo maturation and targeting epitopes that are difficult to express in their native and functionally active conformation.
The application of such technologies have led, among others, to the generation of SYnAbs anti-CD2 rat monoclonal Siplizumab (licensed to MedImmune, MEDI-507), and numerous other functional therapeutic antibodies like our LO-CD2b, LO-TACT anti-CD25 and SYnCCR8, therapeutic mAb against hCCR8 GPCR.
Time to enjoy your free ebook :
"Proven strategies for successful antibodies generation against difficult antigens"
March 28th - March 31st
April 21rst
June 13th - June 16th
Sept 28th
Oct 13th - Oct 15th
Oct 25th - Oct 27th
Nov 2nd - Nov 4th
Nov 14th - Nov 16th
Nov 15th - Nov 18th
Dec 7th - Dec 9th
BioEurope Spring (digital version)
Innovation for Health
BIO International
Knowledge for Growth
BioJapan
BioEurope Fall
Festival of Biologics
PEGS
Medica
BioFIT
Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.
Le projet MENAC a pour objectif de développer de tests innovants non invasifs pour la détection précoce
de différents types de cancers.
Ce projet réalisé en partenariat par les sociétés Volition et Synabs passe par la création d'anticorps monoclonaux
et la mise au point de nouveaux immuno-essais diagnostiques et théranostiques.
Subvention de 1.990.798€
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
+32 (0)71/374.880
BE 0637.716.206